Daxiong Zeng

875 citations
47 papers · 624 indexed · h-index 16
Topics
RNA modifications and cancer (10 papers)Pulmonary Hypertension Research and Treatments (9 papers)Cancer-related molecular mechanisms research (7 papers)
Partner nations
ChinaCanadaUnited States

In The Last Decade

Daxiong Zeng

47 papers receiving 617 citations

Peers

Daxiong Zeng
Comparison fields: 5 of 80
  • Pulmonary and Respiratory Medicine 273
  • Molecular Biology 270
  • Cancer Research 177
  • Oncology 108
  • Immunology 100
Replace Ágnes F. Semsei with:
Ágnes F. Semsei Hungary
Nicholas B. Shannon Singapore
Jiang Geng China
Matthew H. Crouthamel United States
Yi He China
Katharina Sinn Austria
Yun Sun China
Yongqian Jia China
Ting Meng China
Xian Xue China
Daxiong Zeng relative to Ágnes F. Semsei Hungary Ágnes F. Semsei's profile →
Citations per field
00.5×3.1×
Ágnes F. Semsei · 1×
Citations per year

Countries citing papers authored by Daxiong Zeng

Since Specialization
Citations

This map shows the geographic impact of Daxiong Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daxiong Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daxiong Zeng more than expected).

Fields of papers citing papers by Daxiong Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daxiong Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daxiong Zeng. The network helps show where Daxiong Zeng may publish in the future.

Co-authorship network of co-authors of Daxiong Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Daxiong Zeng. A scholar is included among the top collaborators of Daxiong Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daxiong Zeng. Daxiong Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 2
3 18
4 10
5 6
6 22
7 17
8 4
9 38
10 11
11 26
12 27
13 26
14 14
15 2
16 34
17 32
18 16
19 6
20 12

About Daxiong Zeng

Daxiong Zeng is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Immunology, having authored 47 papers that have together received 624 indexed citations. Recurring topics across this work include RNA modifications and cancer (10 papers), Pulmonary Hypertension Research and Treatments (9 papers) and Cancer-related molecular mechanisms research (7 papers). The work is most often cited by research in Cancer Research (177 citations), Pulmonary and Respiratory Medicine (273 citations) and Immunology (100 citations). Daxiong Zeng has collaborated with scholars based in China, Canada and United States. Frequent co-authors include Ran Wang, Wei Lei, Xiansheng Liu, Yongjian Xu, Min Xiang, Junhong Jiang, Jianan Huang, Sijing Zhou, Changguo Wang and Yehan Zhu. Their work appears in journals such as PLoS ONE, Cancer Research and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026